BillionToOne
Aetna Revises Fetal Aneuploidy Screening Policy to Include Natera, BillionToOne Tests
The policy considers cfDNA testing medically necessary in cases such as a risk of alloimmunization and where amniocentesis is declined or contraindicated.
JP Morgan Healthcare Conference, Day 2: CareDx, Thermo Fisher, BillionToOne, Adaptive Biotech, More
Highlights from the second day included BillionToOne's 2024 revenue spike and CareDx's plan to expand indications for its transplant tests.
People in the News at NYGC, Oxford Nanopore, Pacific Biosciences, BillionToOne, NeoGenomics, More
Recently posted executive and academic appointments, promotions, and departures in omics and molecular diagnostics.
Top Five Articles on GenomeWeb Last Week: Illumina, BillionToOne, Foundation Medicine, Qiagen, More
Last week, GenomeWeb's readers were most interested in news about Illumina pricing a $500 million public notes offering.
BillionToOne Raises $130M in Series D Financing Round
The Menlo Park, California-based company will use the funds to expand and scale its prenatal and oncology testing businesses.